Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
[Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China].
OBJECTIVES To investigate the efficacy of 10 mg or 20 mg atorvastatin + long acting antihypertensive in carotid intima-medial thickness ( IMT ) . METHODS 151 patients of Han nationality in South China with mild hypertensive were r and omly divided into 3 groups : atorvastatin 10 mg group ( n = 50 ) receive 10 mg atorvastatin and amlodipine + benazepril ; atorvastatin 20 mg group ( n = 61 ) receive 20 mg atorvastatin and amlodipine + benazepril ; the control group ( n = 40 ) receive amlodipine + benazepril . The patients were detected IMT , vascular function , lipids and inflammatory factor in pretherapy and every 3 months . RESULTS atorvastatin 10 mg or 20 mg groups have significantly change contrast to control group : ( 1 ) IMT was decreased ( P < 0.01 ) . ( 2 ) Deltadia-P% and Deltadia-N% were increased ( P < 0.01 ) . ( 3 ) LDL-C level was decreased by 30 % in a atorvastatin 10 mg group and 40.48 % in 20 mg group respectively ( P < 0.01 ) . CONCLUSION Atorvastatin delays the development of atherosclerosis in hypertensive patients , improves endothelial function , and strengthens the effect of lipid-lowering
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .